---
schema_version: "secwatch.filing_event.v1"
accession: "0001022079-26-000067"
form_type: "8-K"
ticker: "DGX"
cik: "0001022079"
company_name: "QUEST DIAGNOSTICS INC"
filed_at: "2026-07-23T10:46:37+00:00"
generated_at: "2026-07-23T10:50:07.081550+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Quest Diagnostics Q2 revenue up 10.2% to $3.04B; raises FY2026 guidance

## Summary
- Q2 revenue $3.04B (+10.2% YoY), organic growth 10.0%.
- Reported diluted EPS $2.84 (+15% YoY); adjusted diluted EPS $3.12 (+19.1% YoY).
- FY2026 revenue guidance raised to $11.95B-$12.05B; adjusted EPS guidance raised to $11.05-$11.25.
- Q2 cash from operations $597M, up 9.7% YoY.
- Advanced Diagnostics growth (Alzheimer's, cardiometabolic); NY approval for Haystack MRD test.

## SEC filing metadata
- accession: 0001022079-26-000067
- form_type: 8-K
- ticker: DGX
- cik: 0001022079
- company_name: QUEST DIAGNOSTICS INC
- filed_at: 2026-07-23T10:46:37+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000067/0001022079-26-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000067/dgx-20260723.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001022079-26-000067
- JSON: https://secwatch.observer/filing/0001022079-26-000067.json
- Plain text: https://secwatch.observer/filing/0001022079-26-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.